CDSCO finds 20 drug samples from Baddi-Barotiwala-Nalagarh and Kala Amb Area below standards
Photo used for indicative purpose only. Source: Internet
Shimla, Apr 17,
The Central Drugs Standard Control Organization (CDSCO) conducted tests on 931 drug samples in March. out of which 66 samples were found to be below the required standards including 20 of Himachal based pharmaceutical industry. The industrial landscape of Baddi-Barotiwala-Nalagarh (BBN) and Kala Amb of Sirmour district in Himachal Pradesh has long been synonymous with the production of life-saving drugs. However, recent reports have shed light on a concerning trend within this pharmaceutical hub.
Among the drugs that failed the quality tests were some widely used medications including Foxygen-200 and 550 by Legan Healthcare of Parwanoo, Astriparin injection by Astraika Health Care of Baddi, and Pardic-SP tablet manufactured in JMM Laboratory of Sirmaur.
Additionally, Mentor LC tablet by Torque Pharmaceutical located in Jhadmajri, Acemetil-SP by Sigma Softgel and Formulation of Baddi, and Tel Verge H by Bioltus Pharmaceutical of Baddi were also on the list of failed samples.
The CDSCO’s drug alert also highlighted failures in products such as Opisoprot-200 by Pharma industry of Kala Amb Sirmaur, Calcium Carbonate Tablet 500 mg by Pharmaruts Healthcare of Barotiwala, Axiflo-OZ tablet by MC Pharmaceutics industry of Paonta Sahib, and Saluzinc-20 by Salus Pharmaceutics of Baddi, among others. These findings have triggered concerns about the efficacy and safety of these medications.
State Drug Controller Manish Kapoor has taken swift action in response to these findings. Show cause notices have been issued to the concerned pharmaceutical companies, and instructions have been given to recall the substandard stock from the market.
The failures of samples like Tripod-200 by Cytech Medicare industry of Kala Amb, Alerno tablet of Kala Amb industry, and Flutol tablet by Fargen Healthcare industry of Baddi have further underscored the need for stringent quality control measures in the pharmaceutical sector.
The CDSCO’s findings have posed a challenge as now the reputation of this industrial hub, known for its significant contributions to healthcare, faces a critical juncture.
As the investigation unfolds and actions are taken, stakeholders closely watch to see how the pharmaceutical industry in BBN responds. Though noteworthy fact also is that it is not the first time, samples have been found sub standard from here. Also read: Concern mounts over poor quality drugs from Himachal pharma firms/
About the Author
The HimachalScape Bureau comprises seasoned journalists from Himachal Pradesh with over 25 years of experience in leading media conglomerates such as The Times of India and United News of India. Known for their in-depth regional insights, the team brings credible, research-driven, and balanced reportage on Himachal’s socio-political and developmental landscape.
